Biosenic SA

Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO

30 May 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

11 May 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022

08 May 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics announces 2021 full year results

28 Apr 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Secures EUR 5 Million Financing

11 Apr 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to strategically focus on lead cell therapy product ALLOB

28 Mar 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

22 Mar 2022 23:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook

18 Jan 2022 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

22 Dec 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

09 Dec 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Information on the total number of voting rights and shares

08 Dec 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics announces closing of private placement

07 Dec 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement

02 Dec 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

28 Nov 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Provides Third Quarter 2021 Business Update

25 Oct 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development

11 Oct 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)

27 Sep 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics appoints Lieve Creten as interim Chief Financial Officer

20 Sep 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics reports half year 2021 results

07 Sep 2021 22:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA reacts to the press release issued by Hybrigenics

06 Sep 2021 22:00:00 By Nasdaq GlobeNewswire